Pharmacogenetics of morphine: Potential implications in sickle cell disease

被引：21

作者：

Darbari, Deepika S. ^{[1
,2
]}

Minniti, Caterina P. ^{[1
,2
]}

Rana, Sohail ^{[3
]}

van den Anker, John ^{[2
,4
,5
]}

机构：

[1] Childrens Natl Med Ctr, Ctr Canc & Blood Disorders, Washington, DC 20010 USA

[2] George Washington Univ, Sch Med & Hlth Sci, Dept Pediat, Washington, DC 20052 USA

[3] Howard Univ, Coll Med, Dept Pediat, Washington, DC USA

[4] Childrens Natl Med Ctr, Div Pediat Clin Pharmacol, Washington, DC 20010 USA

[5] George Washington Univ, Sch Med & Hlth Sci, Dept Physiol & Pharmacol, Washington, DC 20052 USA

来源：

AMERICAN JOURNAL OF HEMATOLOGY | 2008年 / 83卷 / 03期

关键词：

D O I：

10.1002/ajh.21027

中图分类号：

R5 [内科学];

学科分类号：

1002 [临床医学]; 100201 [内科学];

摘要：

Morphine is frequently used to treat painful episodes associated with sickle cell disease (SCD) but may fail to provide adequate analgesia in many patients. This concise review focuses on unique disease related changes in physiologic variables associated with SCD that impacts pharmacokinetics and pharmacodynamics of morphine and may contribute to the variability in analgesia. Emerging evidence suggests that the allelic variants in the genes involving the opioid (UGT2B7, OPRM1, and ABCB1 genes) and nonoploid system (COMT gene) can alter the efficacy of morphine.

引用

页码：233 / 236

页数：4

共 45 条

[1]

RENAL ABNORMALITIES IN SICKLE-CELL DISEASE [J].